References
- Weisser H, Krieg M. Benign prostatic hyperplasia – the outcome of age-induced alteration of andro- gen-estrogen balance? Urologe A 1997;36:3–9
- Sciarra F. Sex steroids and epidermal growth factor in benign prostatic hyperplasia (BPH). Ann NY Acad Sci 1995;761:66–78
- Suzuki K, Ito K, Ichinose Y, Kurokawa K, Suzuki T, Imai K, et al. Endocrine environment of benign prostatic hyperplasia: prostate size and volume are correlated with serum estrogen concentration. Scand J Urol Nephrol 1995;29:65–8
- Gann PH, Hennekens CH, Longcope C, Verhoek-Oftedahl W, Grodstein F, Stampfer MJ. A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia. Prostate 1995;26:40–9
- Stege R, Carlstrom K. Testicular and adreno- cortical function in healthy men and in men with benign prostatic hyperplasia. J Steroid Biochem Mol Biol 1992;42:357–62
- Farnsworth WE. Estrogen in the etiopathogenesis of BPH. Prostate 1999;41:263–74
- Farnsworth WE. Roles of estrogen and SHBG in prostate physiology. Prostate 1996;28:17–23
- Krieg M, Nass R, Tunn S. Effect of aging on endogenous level of 5 alpha-dihydrotestosterone, testosterone, estradiol, and estrone in epithelium and stroma of normal and hyperplastic human prostate. J Clin Endocrinol Metab 1993;77:375–81
- Suzuki K, Inaba S, Takeuchi H, Takezawa Y, Fukabori Y, Suzuki T, et al. Endocrine environ- ment of benign prostatic hyperplasia – relationships of sex steroid hormone levels with age and the size of the prostate. Nippon Hinyokika Gakkai Zasshi 1992;83:664–71
- Donike M, Zimmermann J. Detection of exo- genous testosterone by GC/MS in routine doping analysis. Symp Anal Steroids 1984;6:10–1
- Huggins C, Hodges C. Studies on prostatic cancer. Effect of castration, of estrogen and androgen injections on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293–7
- Zgliczy ski S, Baranowska B, Szymanowski J. Zmiany hormonalne w przero cie i raku gruczo u krokowego. Endokr Pol 1979;4:319–30
- Partin AW, Oesterling JE, Epstein JI, Horton R, Walsh PC. Influence of age and endocrine factors on the volume of benign prostatic hyperplasia. J Urol 1991;145:405–9
- Rannikko S, Adlercreutz H. Plasma estradiol, free testosterone, sex hormone binding globulin binding capacity, and prolactin in benign prostatic hyperplasia and prostatic cancer. Prostate 1983; 4:223–9
- Swerdloff RS, Wang C. Androgen deficiency and aging in men. West J Med 1993;159:579–85
- Lagiou P, Mantzoros CS, Tzonou A, Signorello LB, Lipworth L, Trichopoulos D. Serum steroids in relation to benign prostatic hyperplasia. Oncology 1997;54:497–501
- Bartsch W, Becker H, Pinkenburg FA, Krieg M. Hormone blood levels and their inter-relationships in normal men and men with benign prostatic hyperplasia (BPH). Acta Endocrinol 1979;90:727–36
- Kumar VL, Wadhwa SN, Kumar V, Farooq A. Androgen, estrogen, and progesterone receptor contents and serum hormone profiles in patients with benign hypertrophy and carcinoma of the prostate. J Surg Oncol 1990;44:122–8
- Schweikert HU, Tunn UW, Habenicht UF, Arnold J, Senge T, Schulze H, et al. Effects of estrogen deprivation on human benign prostatic hyperplasia. J Steroid Biochem Mol Biol 1993;44:573–6
- Hammond GL, Kontturi M., Vihko P, Vihko R. Serum steroids in normal males and patients with prostatic diseases. Clin Endocrinol 1978;9:113–21
- Matzkin H, Chayen R, Goldfarb H, Gilad S, Braf Z. Laboratory monitoring of androgenic activity in benign prostate hypertrophy treated with a 5 alpha-reductase inhibitor. Clin Chem 1992;38:1304–6
- Brochu M, Belanger A. Comparative study of plasma steroid and steroid glucuronide levels in normal men and in men with benign prostatic hyperplasia. Prostate 1987;11:33–40